The new Transcreener cGAMP cGAS Assay directly measures the product cGAMP, in a cGAS enzymatic reaction allowing researchers to screen vast compound libraries for modulators of the enzyme. The assay will be used to discover and develop new treatments for autoimmune diseases and cancer by strategically targeting the cGAS-STING pathway. Researchers at BellBrook Labs have developed a high throughput screening (HTS) compatible biochemical assay....
BioTek's complete line of multi-mode microplate readers have now earned Transcreener HTS Assay certifications from BellBrook Labs.
Performance of BioTek readers including the Synergyâ„¢ Neo2 and Cytationâ„¢ 5 have been confirmed as meeting validation requirements across BellBrook's supported Fluorescence Intensity, Fluorescence Polarization and TR-FRET detection modes. Synergy Neo2 is designed for speed and ultra high performance, incorporating BioTek's patented Hybrid Technologyâ„¢, with its independent optical paths that ensure uncompromised performance in all detection...
Speed up your chemotaxis research with Acumen eX3
Oct 3, 2010TTP LabTech has today announced a high throughput solution for chemotaxis research using the AcumenÂ® eX3 microplate cytometer and the iuvoTM Chemotaxis Assay Plate from BellBrook Labs. Using this system, approximately four-fold time savings were achieved compared to a similar method using automated microscopy and off-line data processing
BioTekâ€™s Synergy H4 Hybrid Reader Is Transcreener Approved
Mar 15, 2010BioTek's new SynergyTM H4 Hybrid Microplate Reader has received TranscreenerÂ® approval from BellBrook Labs (Madison, WI). The approval extends to the Transcreener Fluorescence Polarization, Far Red, Red Fluorescence (FI) and Red TR-FRET assays, and means that the Synergy H4 meets strict standards in instrument setup and assay performance.
TTP LabTech hosts Acumen screening meeting in the US
Mar 9, 2010TTP LabTech has announced the date for its 2010 US Acumen User Group Meeting (UGM). To be held on May 18-19 at the British Consulate-General in Cambridge, MA., the UGM will be open to existing users and high content screening researchers who are interested in how the Acumen eX3 could benefit their research.